Defending psychiatry or defending the trivial effects of therapeutic interventions? A citation content analysis of an influential paper

I. A. Cristea^{1,2} and F. Naudet^{1*}

¹ Meta-Research Innovation Center at Stanford (METRICS), Stanford University, Palo Alto, USA

² Department of Clinical Psychology and Psychotherapy, Babes-Bolyai University, Cluj-Napoca, Romania

Aims. Leucht *et al.* in 2012 described an overview of meta-analyses of the efficacy of medication in psychiatry and general medicine, concluding that psychiatric drugs were not less efficacious than other drugs. Our goal was to explore the dissemination of this highly cited paper, which combined a thought provoking message with a series of caveats.

Methods. We conducted a prospectively registered citation content analysis. All papers published before June 1st citing the target paper were independently rated by two investigators. The *primary outcome* coded dichotomously was whether the citation was used to justify a small or modest effect observed for a given treatment. Secondary outcomes regarded mentioning any caveats when citing the target paper, the point the citation was making (treatment effectiveness in psychiatry closely resembles that in general medicine, others), the type of condition (psychiatric, medical or both), specific disease, treatment category and specific type. We also extracted information about the type of citing paper, financial conflict of interest (COI) declared and any industry support. The primary analysis was descriptive by tabulating the extracted variables, with numbers and percentages where appropriate. Co-authorship networks were constructed to identify possible clusters of citing authors. An exploratory univariate logistic regression was used to explore the relationship between each of a subset of pre-specified secondary outcomes and the primary outcome.

Results. We identified 135 records and retrieved and analysed 120. Sixty-three (53%) quoted Leucht *et al.*'s paper to justify a small or modest effect observed for a given therapy, and 113 (94%) did not mention any caveats. Seventy-two (60%) used the citation to claim that treatment effectiveness in psychiatry closely resembles that in general medicine; 110 (91%) paper were about psychiatric conditions. Forty-one (34%) papers quoted it without pointing towards any specific treatment category, 28 (23%) were about antidepressants, 18 (15%) about antipsychotics. Forty (33%) of the citing papers included data. COIs were reported in 55 papers (46%). Univariate and multivariate regressions showed an association between a quote justifying small or modest effects and the point that treatment effectiveness in psychiatry closely resembles that in general medicine.

Conclusions. Our evaluation revealed an overwhelmingly uncritical reception and seemed to indicate that beyond defending psychiatry as a discipline, the paper by Leucht *et al.* served to lend support and credibility to a therapeutic myth: trivial effects of mental health interventions, most often drugs, are to be expected and therefore accepted.

Protocol registration: <https://osf.io/9dqat/>

Received 11 September 2017; Accepted 28 October 2017; First published online 29 November 2017

Key words: Citation analysis, efficacy, drugs, medicine, psychiatry.

Introduction

In an influential paper, Leucht *et al.* (2012) described an overview of meta-analyses of the efficacy of medication in psychiatry and general medicine, with the declared goal of putting the efficacy of the former into perspective. Effect sizes of general medicine medication (median 0.37, mean 0.45, 95% CI 0.37–0.53) and

psychiatric drugs (median 0.41, mean 0.49, 95% CI 0.41–0.57) were similar and in general modest, leading the authors to conclude that ‘psychiatric drugs were not generally less efficacious than other drugs’ (p. 97). The authors were very cautious in interpreting their findings, explicitly stating (p. 101) that (a) ‘any comparison of different outcomes in different diseases can only serve the purpose of a qualitative perspective’ and (b) ‘the increment of improvement by drug over placebo must be viewed in the context of the disease’s seriousness, suffering induced, natural course, duration, outcomes, adverse events and societal values’. Caveats were explicitly addressed and delineated,

* Address for correspondence: Florian Naudet, Clinical Investigation Center (INSERM 1414), Rennes University Hospital, 2 rue Henri Le Guilloux, 35000 Rennes, France.
(Email: florianaudet@gmail.com)

such as those related to the use of different categories of outcomes in psychiatry versus general medicine. For instance, a given effect size observed on a rating scale on which changes in score have an opaque clinical meaning might be less relevant to attain than a smaller effect size on important health outcomes such as mortality or major, clearly observable and quantifiable, events (e.g., heart attack, stroke).

Over the 5 years since its publication, this paper has become highly cited, with enough citations to place it in the top 1% of the academic field of Psychiatry/Psychology according to Clarivate Analytics InCites™ Essential Science indicators, which are based on a highly cited threshold for field and publication year. In Scopus, as of June 2017, the paper had been cited 135 times. It offers therefore an interesting case in citation content analysis because its assumed exclusively qualitative perspective, as well the array of caveats and restrictions that are attached to its reported quantitative findings, offer ample opportunities for distortion, misinterpretation and exploitation as support for *a priori* agendas or *post hoc* hypothesising.

Therefore, our goal was to explore the reception and dissemination of this paper in the scientific medical literature, in particular which aspects of its message were taken on, whether it was cited with due consideration to its caveats or, conversely, whether it was cited for the most part uncritically, as an essential piece in a narrative maintaining that the low efficacy of some psychiatric medications or therapies was not an issue of concern.

Method

The study protocol was registered at the Open Science Framework (<https://osf.io/9dqat/>). The study is a pre-specified citation content analysis.

Eligibility criteria

All published papers citing the target paper (Leucht *et al.* 2012), regardless of their type or whether they included data or not, were eligible. Papers in English, German, French, Italian, Spanish and Romanian were considered. For citing papers, no restrictions were placed over the types of conditions or domains, the population, the interventions or comparators that were directly studied or discussed.

Search

Scopus was chosen as it is more inclusive than other databases like Web of Science. It was searched to identify citing papers (June 1, 2017).

Outcomes

The *primary outcome* coded dichotomously (yes/no) was whether or not the citation of target paper was used to justify a small or modest ES observed for a given treatment. This categorisation relied on both (a) the wording used by the authors quoting the paper and (b) Cohen's classification (Cohen, 1988) defining small, modest and large effect sizes. The verbatim quote referencing the target paper was also extracted for qualitative analysis.

Secondary outcomes refer to the quote in which the authors of the citing paper referenced the target paper, as well as to the citing paper as a whole.

For the quote in which the target paper was referenced, the following information was extracted: (a) any mention of caution or caveats; (b) the point that the citation is making (the notion that treatment effectiveness in psychiatry closely resembles that in general medicine, or the notion that treatment effectiveness in general medicine closely resembles that in psychiatry, or the notion that treatments have large effects, or the notion that treatments have moderate effects, or the notion that treatments have small effects, or discussion of small effects not covered by the previous categories, such as a small effect claimed by comparison with the target paper, described as relevant but without making the parallel with general medicine, or other points when none of the previous categories applied); (c) the type of condition discussed (psychiatric, general medical condition or both); (d) the type of disease discussed; (e) the category of treatment discussed (drug, device, psychological intervention, surgery); and (f) the specific type of treatment.

For the citing paper as a whole, we extracted information on (a) type of paper [experimental, defined as systematically collecting and analysing data, including systematic reviews and qualitative research, or non-experimental (i.e., viewpoint, editorial, narrative reviews)]; (b) mention of any conflict of interest (COI) listed at the end of the paper; (c) industry involvement, including partial, in funding the paper; and (d) name of the funder.

Data extraction

Two raters (IC and FN) independently extracted information about the outcome measures from each of the papers citing the target article and subsequently coded it into the categories mentioned. All disagreements were resolved by discussion.

Data synthesis

The primary analysis was descriptive and focused on tabulating and presenting the extracted variables. Verbatim examples were extracted and presented for

the primary outcome. Outcomes were presented as numbers and percentages, where possible. Co-authorship networks were constructed to identify possible clusters of authors citing the paper.

An exploratory univariate logistic regression was used to explore the relationship between the primary outcome (use of the quote to justify a small or modest ES) and each of a subset of secondary outcomes pre-specified in the protocol: (a) type of paper, (b) COI, (c) point made, coded dichotomously (the notion that treatment effectiveness in psychiatry closely resembles that in general medicine, as stated in the Leucht *et al.*'s paper *versus* other points), (d) type of condition and (e) type of treatment. All associations with a p -value <0.25 were subsequently explored in a multivariate logistic regression. All analyses were done in R version 3.4.1 (2017-06-30, The R Foundation for Statistical Computing).

Results

Searches

The search identified 135 citing papers in Scopus. From these, 15 were excluded because of language ($n = 4$), full-text unavailability ($n = 10$) or absence of citation of the target paper ($n = 1$). Consequently, 120 papers were retained for analysis. All extracted information and the list of included citing papers is available in Supplementary Table 1. Among these, 63 (53%) quoted Leucht *et al.*'s paper to justify a small or modest ES observed for a given therapeutic, and 113 (94%) did not mention any caveats. Among the seven papers mentioning caveats, one was a comment on the target paper (Seemuller *et al.* 2012), and another was co-authored by its lead author, Stefan Leucht (Leucht *et al.* 2015).

Quote in which the target paper is referenced

Seventy-two (60%) used the citation to claim that treatment effectiveness in psychiatry closely resembles that in general medicine, while one (1%) used it to claim that treatment effectiveness in general medicine closely resembles that in psychiatry. Sixteen (13%) quoted Leucht *et al.* to support the idea that treatments have large effects, five (4%) moderate effects and three (3%) small effects. Seven (6%) used it to argue that small effects are relevant without making the parallel with general medicine and 16 (13%) made other points (see Supplementary table 1 for the detailed reasons). A total of 110 (91%) paper were about psychiatric conditions, eight (7%) were about general medical conditions (among these, four by the same authors) and two (2%) were about both conditions. Table 1 gives

examples of these different categories with verbatim formulations extracted from the citing papers.

Forty-two (35%) papers quoted the paper in a general context without pointing towards any specific condition, 34 (28%) quoted it for affective disorders, 19 (16%) for psychosis, seven (6%) for addiction and seven (6%) for attention deficit hyperactivity disorder (ADHD). The remaining 11 (9%) were about various other conditions.

Ninety (75%) used the paper to make a comment on the effects of drugs, 14 (12%) on psychological interventions and nine (7%) in the general context of treatments (including all interventions). In the remaining seven (6%), the paper was used to comment on a surgical intervention ($n = 3$), a device ($n = 2$), a nutritional intervention ($n = 1$) and an educational programme ($n = 1$).

More specifically, among these categories, 41 (34%) papers quoted it without pointing towards any specific category of treatment, 28 (23%) were about antidepressants and 18 (15%) about antipsychotics. The remaining 37 (31%) were about various treatments.

Citing paper as a whole

Leucht *et al.*'s paper was cited in 40 (33%) experimental papers. COIs were reported in 55 papers (46%), 51 (42%) papers reported no COIs, whereas in 14 (12%) this information was missing. Ten (8%) studies had a direct industry sponsorship, including six from Lundbeck about nalmefene ($n = 4$) and vortioxetine ($n = 2$).

Co-authorship network

The co-authorship network is presented in Fig. 1. We identified a big cluster of interconnected authors citing the paper, although the vast majority of citations were done by a constellation of independent authors. The network involves 521 individual authors with a median number of citation of 1 (minimum = 1, maximum = 5).

Logistic regressions

Logistic regressions are presented in Table 2. In univariate analysis, we found an association between a quote justifying small or modest effects and the point that treatment effectiveness in psychiatry closely resembles that in general medicine. This association survived in multivariate analysis. In addition, the context of a psychological intervention was associated in multivariate analysis with citation in a context of small or medium effects. No significant associations were found for the other explanatory variables.

Table 1. Represented verbatim extracts from the citing papers illustrating the primary and secondary variables

Citing paper	Paper	Quote	Modest/ Small ES	Caution	Point made	Condition	Treatment	COI
Cuijpers <i>et al.</i> (2017)	Non-exp	'These are not large differences, but are still remarkable in this population of patients with treatment-refractory chronic depression. Medicine, psychiatric or non-psychiatric, can only rarely work miracles and the median efficacy of standard drug therapies, both in medicine and psychiatry, hover around effect sizes of 0.3 and 0.4. The efficacy of around 0.3 in effect size of CBASP compared with nonspecific bona fide psychotherapy would represent an addition to the armamentarium in psychiatry as great as, or as small as, many other advances in medicine.'	Y	N	Psych = Gen	Psych	Psy	N
Mann <i>et al.</i> (2016)	Exp	'However the effect sizes reported in the target population are well in the range for approved medicinal products in general medicine and psychiatry, including alcohol dependence.'	Y	N	Psych = Gen	Psych	Drug	Y
Goodwin <i>et al.</i> (2016)	Non-exp	'Effect sizes in psychiatry, in common with the rest of medicine, are moderate (Leucht <i>et al.</i> 2012) but deliver worthwhile patient benefit. Nihilism about the results of RCTs should be avoided.'	Y	N	Psych = Gen	Psych	Drug	Y
Taylor <i>et al.</i> (2014)	Exp	'Thirdly, even the small effect sizes calculated for antidepressants in acute treatment are not dissimilar to those observed in medical conditions such as hypertension (effect size for ACE inhibitors in prevention of cardiovascular events is 0.16) and acute stroke (effect size of thrombolysis on survival is 0.11). As with the use of other antidepressants, agomelatine might be expected to result in the improvement of perhaps three quarters of patients, although most these will be placebo responders.'	Y	N	Psych = Gen	Psych	Drug	Y
Aleman <i>et al.</i> (2014)	Non-exp	'Recently, Leucht <i>et al.</i> showed that clinical efficacy of depression treatment is not inferior to that of most somatic treatments. Despite the relatively low efficacy of psychotherapy, rTMS and pharmacotherapy, these treatments are of great use for depressive patients.'	Y	N	Psych = Gen	Psych	Device	N
De Vries <i>et al.</i> (2016)	Exp	'Effect sizes for the drug-placebo difference were unaffected by inclusion of baseline severity as a main effect or in interaction with group, but they were generally smaller than a criterion for clinical significance previously used (although without clear justification) for major depression ($d = 0.5$). However, it has been shown that effect sizes exceeding 0.5 are not achieved by most current treatments, either in psychiatry or in general medicine. Furthermore, clinical significance is both context- and disorder-specific.'	Y	Y	Psych = Gen	Psych	Drug	N

Continued

Table 1. Continued

Citing paper	Paper	Quote	Modest/ Small ES	Caution	Point made	Condition	Treatment	COI
Jonas <i>et al.</i> (2015)	Exp	'Meta-analyses of placebo-controlled drug studies in pain, depression, hypertension, ulcer treatment and other areas often report a similar magnitude of specific treatment effects compared with non-specific effects.'	N	N	Gen = Psych	Gen	Surg	N
Chan <i>et al.</i> (2017)	Exp	'Despite that existing stimulant treatment (primarily by methylphenidate, MPH) falls short of a cure to eradicate ADHD, it remains the most efficacious treatment for short-term symptomatic relief of ADHD with effect sizes ranging from 0.78 to 0.96.'	N	N	Large effect	Psych	Drug	N
Waszczuk <i>et al.</i> (2017)	Exp	'Treatment effects on PTSD and LRS were moderate and typical of psychiatric interventions.'	Y	N	Moderate effect	Psych	Psy	NR
Bisson <i>et al.</i> (2015)	Non-exp	'The effect sizes for drug treatments compared with placebo are inferior to those reported for psychological treatments with a trauma focus over waiting list or treatment as usual controls. ^{33 47} Effect sizes with drug treatment are similar to those observed from use of antidepressants for depression compared with placebo.'	N	N	Small effect	Psych	Drug	N
Sayer <i>et al.</i> (2015)	Exp	'Consequently, the actual realized impact of psychotherapy on impaired veterans is likely small. Measures of effect size should be evaluated in the context of the costs and potential population benefits. For example, the prophylactic use of aspirin to prevent heart attacks in those with, or at risk of, cardiovascular disease has a small effect, but is inexpensive and acceptable to patients. Because it is easily implemented and accessed, expressive writing's total population effect could be larger than that of more potent, but less utilised, interventions.'	Y	Y	Relevant small effects	Psych	Psy	N
Hoskins <i>et al.</i> (2015)	Exp	'The effect sizes for pharmacological treatments for PTSD compared with placebo are low and inferior to those reported for psychological treatments with a trauma focus over waiting-list or treatment as usual controls. They are, however, similar to those found for antidepressants for depression compared with placebo.'	Y	N	Relevant small effect	Psych	Drug	N
Messori <i>et al.</i> (2013)	Exp	'In other disease conditions, early trials of potentially lower quality seem to have yielded larger differences than more recent ones.'	N	N	Other	Gen	Surg	N

COI, conflict of interest; ES, effect size; Exp, experimental; N, no; Non-exp, non-experimental; Gen, general medicine; Psych, Psychiatry; Psy, psychological treatment; Surg, surgery; Y, yes.

Fig. 1. Co-authorship researcher networks. Each circle represents one author (larger diameter indicates a larger number of publication by this author) and each line connecting two authors indicates the presence of at least one publication they have co-authored (larger diameter indicates a larger number of publication in common). All analyses were performed using the igraph library in R.

Discussion

Summary of evidence

We examined the dissemination of a highly influential paper (Leucht *et al.* 2012) in the scientific medical literature by means of descriptive citation analysis and exploratory regression analysis. This particular paper provided an interesting case study, because, apart from being highly cited, it combined a thought-provoking main finding (i.e., psychiatric drugs are no less effective than drugs in general medicine) with an exhaustive and judicious description of caveats qualifying it. The authors went to great length to underscore their interpretation can only be qualitative and label their analysis as solely intended to put the effectiveness of psychiatric drugs into perspective. It was thus relevant to examine whether the reception on the paper has taken on the whole ‘package’, including the qualitative essence of its findings and the

limitations attached, or rather focused on selecting the fragments that could be then molded into support for *a priori* agendas or *post hoc* hypothesising.

Over half of the citing articles used the reference to Leucht and colleagues in a context where it served to justify small or modest effects. Our regression analysis suggests this might especially be the case when the point made was in line with the main claim of Leucht’s paper (the idea that treatment effectiveness in psychiatry closely resembles that in general medicine). Interestingly, only one paper reversed this idea by citing the target paper to argue that treatment effectiveness in general medicine closely resembles that in psychiatry. In addition, while three quarters of the quotes commented on drugs, some were made to comment on other interventions, such as psychological interventions. It is possible that the contingent of quotes about psychological interventions are a particular subgroup, dealing with therapies with

Table 2. Univariate and multivariate logistic regression exploring association between a citation to justify small or medium effects and pre-specified explanatory variables

Variable	Odds ratio [95% confidence interval]	Adjusted Odds Ratio [95% confidence interval]*
Type of paper (ref = experimental)	1.35 [0.63–2.91]	†
Type of condition (ref = psychiatric)	2.8 [0.74–13.51]	0.72 [0.06–13.45]
Type of treatment (ref = drugs)		
All treatments	0.44 [0.09–1.77]	0.23 [0.03–1.56]
Psychological	2.19 [0.68–8.45]	7.59 [1.45–51.64]
Other	0.35 [0.05–1.72]	1.04 [0.08–21.73]
Point made: psychiatry = general medicine (ref = other)	13.00 [5.49–33.62]	29.59 [9.01–137.00]
Conflict of interest (ref = no)*	1.83 [0.85–4.00]	1.64 [0.55–4.87]

Some exploratory variables were dichotomized for the purpose of modelling.

*14 missing data.

†Type of paper did not survive univariate analysis (p -value >0.25), therefore the multivariate logistic regression only explored the link between a citation to justify small or medium effects and A/type of condition, B/type of treatment, C/point made and D/conflict of interest.

particularly trivial effects (Sayer *et al.* 2015). It is worth noting that Leucht and colleagues did not include any meta-analyses of psychological interventions, a fact which excluded the possibility of citing the paper to justify a certain effect. Conversely, for psychotropic drugs, such as for instance the effectiveness of methylphenidate for ADHD, some authors referenced Leucht *et al.* in lieu of the original meta-analysis included in the overview. Moreover, the paper was cited uncritically. Only seven of the 120 analysed papers mentioned any caveats. Out of these, one was a comment on the target paper (Seemuller *et al.* 2012), and another was co-authored by its lead author, Stefan Leucht (Leucht *et al.* 2015). In spite of the original authors' insistence on caveats, the subsequent citing literature seems to have overwhelmingly ignored them.

Interestingly, ten of the papers benefited from industry support, with the same pharmaceutical corporation being involved in six of these. Though these numbers are small, they do point to the possibility of the industry becoming sensitive to a potentially reassuring scientific justification of small effects and we would not be surprised to find Leucht *et al.* referenced as an argument in drug approval documentation. This would represent a dangerous path to follow, as evidence is already accruing that the bar is too low for drug approvals by regulatory agencies (Downing *et al.* 2014; Naci *et al.* 2017), as it was the case for the very recent approval of the paliperidone 3-month injection by the EMA (Ostuzzi *et al.* 2017).

These findings further supports our thesis that the reception of Leucht *et al.* in the subsequent scientific research – and indirectly what elevated this paper to highly cited status – was a case of citation bias, by

systematically ignoring content that conflicted with the narrative one aimed to advance (Greenberg, 2009). Of note, such biases are not surprising since previous citation content analyses revealed a plethora of citation distortions (Greenberg, 2009), and also highlighted worrisome issues with the way highly cited papers are subsequently used in the literature, the same data being interpreted antithetically by different investigators, depending on their prior support for one or the other side of the evidence (Tatsioni *et al.* 2007). Undoubtedly, scientific journals may establish clearer rules on their requirements for correct citation and more effort can be invested in the peer review phase to aid accurately checking references and detecting possible misleading citations. However, there are other qualities that cannot be forced upon scientists by means of policy and reporting guidelines, such as being reflective. Readers should always remain vigilant and critical.

Limitations

In the first draft of this paper, we suggested that the specific distortions we identified might reveal something about the psychiatric profession's desire to be integrated with general medicine as described by Joanna Moncrieff (Moncrieff, 2008). However, a reviewer suggested that our citation of Moncrieff was not quite accurate, pointing to the fact that she examined psychiatrists' sense of identity from a historical perspective, referring in particular to the period in the 1950s and 1960s when psychiatrists were considered 'second-class' doctors, working in asylums rather than in hospitals. While it is possible that some of that

spirit might have survived in modern psychiatrists, we may very well have been distorting the initial idea of the paper, so as to fit it into our own narrative. Therefore, we were adding, albeit unintentionally, a potential citation distortion. We decided to discuss this example here as an illustration of how easy it is to be swayed by one's own 'story-telling' and to speculatively decontextualise and interpret previously published literature as supportive.

Because the data we collected were very subjective, we resorted to two independent extractions. Nevertheless, to make our judgement, we relied on both the wording used by the authors quoting the paper and Cohen's classification (Cohen, 1988) defining small, modest and large effect sizes. Finding a more objective method of quantification would have been impossible given that the authors of the citing papers operate with different notions of small or modest. Moreover, results of our regression analyses should be interpreted cautiously, as such analyses are only exploratory and prone to residual confounding. In addition, our sample of citing papers was small and estimates of regression analyses may be 1/underpowered to uncover subtler associations as for example with COIs and 2/overly imprecise for identified associations (large confidence intervals).

Perspective

It is interesting to note that, with the exception of ADHD, the citations making use of Leucht *et al.* were about psychiatric conditions and treatments for which effectiveness was shown to be small or modest to moderate at best. For instance, antidepressants in the treatment of affective disorders were consistently shown to have small magnitude benefits (Jakobsen *et al.* 2017), particularly when corrected for publication bias (Turner *et al.* 2008). For antipsychotics for psychotic disorders, a very similar picture emerged with moderate overall effects, further reduced to small effects when corrected for small sample bias and publication bias (Turner *et al.* 2012; Leucht *et al.* 2017). The influential paper of Leucht and colleague provided on many occasions a narrative normalizing such low efficacy: it was particularly exploited to feed into 'a story' in which modestly effective psychiatric treatments were normalised by purporting a seeming equivalence of psychiatry with general medicine. The paper was summoned as proof of this equivalence and its quantitative findings were regularly referenced. Effect estimations obtained or discussed in a citing paper were compared to ESs in the Leucht *et al.* overview of meta-analyses, seen as some sort of benchmark against which the intervention in question can be weighted. The absence of any mentioning of caveats is likely to

mislead the reader of the citing paper into forgetting that while numbers might seem similar, that impression is illusory. An effect size is not reducible to just numbers and the very idea of a small, medium or large effect (Cohen, 1988) is intricately interwoven with the type of outcome. A small ES for a psychiatric scale can simply mean a 1 or 2 points intensity change for a symptom rated on a Likert-type scale. However, it could also literally mean lives saved or, conversely, almost nothing at all, depending on whether it was observed on an outcome like a life-threatening event, or on a surrogate outcome with disputed clinical relevance, such as glycated haemoglobin for diabetes (Boussageon, 2014). In addition, effect sizes depend on variability and may appear higher in small trials of highly selected population than in large-scale pragmatic studies. The fact that the citing literature overwhelmingly obliterated this part is of concern. This entire crucial conversation is by-passed when one authoritatively cites Leucht *et al.*'s paper. If psychiatry is like general medicine, the storyline seems to go, one need not worry about finding only modest, and often trivial, effects for psychiatric drugs or other treatments, as this is exactly what should be expected.

Conclusion

Leucht and colleagues' overview of meta-analyses had the explicit aim of putting the effectiveness of psychiatric drugs into perspective by relating it to other fields of medicine and, as an immediate consequence, by defending psychiatry from 'deep mistrust' (p. 97) and mounting criticism. Our survey on the paper's dissemination in the scientific literature over the past 5 years points to its overwhelmingly uncritical reception. It also seems to indicate that beyond defending psychiatry as a discipline, the paper served to lend support and credibility to a therapeutic myth: trivial effects of mental health interventions, most often drugs, are to be expected and therefore accepted.

Post scriptum

To a reader interested in citing our work, please contact us to choose a correct wording. We will not endorse claims such as 'general medicine is as bad as psychiatry' or 'psychiatry is as bad as evidence-based medicine', but would be delighted to see citations of our work suggesting that some clinical sense and critical thinking are welcome to avoid spin, decontextualisation and oversimplification of important issues in the field of therapeutics.

Supplementary material

The supplementary material for this article can be found at <https://doi.org/10.1017/S2045796017000750>.

Financial support

IC was funded Laura and John Arnold Foundation and the Romanian National Authority for Scientific Research and Innovation, CNCS – UEFISCDI, project number PN-II-RU-TE-2014-4-1316 (awarded to Ioana A. Cristea), none of which had any role in the preparation of the manuscript or decision to submit. FN is funded by Laura and John Arnold Foundation, Fondation Pierre Deniker and Rennes University Hospital (CORECT: COMité de la Recherche Clinique et Translationnelle), who had no role in the preparation of the manuscript or decision to submit.

Conflict of interest

Both authors have completed the Unified Competing Interest form at http://www.icmje.org/coi_disclosure.pdf (available on request from the corresponding author) and declare that: (1) No authors have support from any company for the submitted work; (2) FN has relationships (travel/accommodation expenses covered/reimbursed) with Servier, BMS, Lundbeck and Janssen who might have an interest in the work submitted in the previous 3 years; (3) No author's spouse, partner or children have any financial relationships that could be relevant to the submitted work; and (4) none of the authors has any non-financial interests that could be relevant to the submitted work.

Ethical standard

None.

Availability of data and materials

All extracted data are available in the main text and in the supplementary material.

References

- Aleman A, Slotema CW, Sommer IE (2014). rTMS deserves a fair chance as a novel treatment for depression. *Acta Psychiatrica Scandinavica* **130**, 324–325.
- Bisson JI, Cosgrove S, Lewis C, Robert NP (2015). Post-traumatic stress disorder. *BMJ* **351**, h6161.

- Boussageon R (2014). Cardiovascular outcome trials of glucose-lowering strategies in type 2 diabetes. *The Lancet* **384**, 1096–1097.
- Chan MH, Leung PW, Ho TP, Hung SF, Lee CC, Tang CP, Cheung KC, Ching FY, Chan FH, Chen LH, Garcia-Barcelo M, Sham PC (2017). Are psychiatric comorbidities and associated cognitive functions related to treatment response to methylphenidate in boys with attention-deficit/hyperactivity disorder? *Neuropsychiatric Disease and Treatment* **13**, 1071–1080.
- Cohen J (1988). *Statistical Power Analysis for the Behavioral Sciences*. Erlbaum: New York.
- Cuijpers P, Huibers MJ, Furukawa TA (2017). The need for research on treatments of chronic depression. *JAMA Psychiatry* **74**, 242–243.
- de Vries YA, de Jonge P, van den Heuvel E, Turner EH, Roest AM (2016). Influence of baseline severity on antidepressant efficacy for anxiety disorders: meta-analysis and meta-regression. *The British Journal of Psychiatry* **208**, 515–521.
- Downing NS, Aminawung JA, Shah ND, Krumholz HM, Ross JS (2014). Clinical trial evidence supporting FDA approval of novel therapeutic agents, 2005–2012. *JAMA* **311**, 368–377.
- Goodwin GM, Haddad PM, Ferrier IN, Aronson JK, Barnes T, Cipriani A, Coghill DR, Fazel S, Geddes JR, Grunze H, Holmes EA, Howes O, Hudson S, Hunt N, Jones I, Macmillan IC, McAllister-Williams H, Miklowitz DR, Morriss R, Munafo M, Paton C, Saharkian BJ, Saunders K, Sinclair J, Taylor D, Vieta E, Young AH (2016). Evidence-based guidelines for treating bipolar disorder: revised third edition recommendations from the British Association for Psychopharmacology. *Journal of Psychopharmacology* **30**, 495–553.
- Greenberg SA (2009). How citation distortions create unfounded authority: analysis of a citation network. *BMJ* **339**, b2680.
- Hoskins M, Pearce J, Bethell A, Dankova L, Barbui C, Tol WA, van Ommeren M, de Jong J, Seedat S, Chen H, Bisson JI (2015). Pharmacotherapy for post-traumatic stress disorder: systematic review and meta-analysis. *The British Journal of Psychiatry* **206**, 93–100.
- Jakobsen JC, Katakam KK, Schou A, Hellmuth SG, Stallknecht SE, Leth-Moller K, Iversen M, Banke MB, Petersen IJ, Klingenberg SL, Krogh J, Ebert SE, Timm A, Lindschou J, Gluud C (2017). Selective serotonin reuptake inhibitors versus placebo in patients with major depressive disorder. A systematic review with meta-analysis and Trial Sequential Analysis. *BMC Psychiatry* **17**, 58.
- Jonas WB, Crawford C, Colloca L, Kaptchuk TJ, Moseley B, Miller FG, Kriston L, Linde K, Meissner K (2015). To what extent are surgery and invasive procedures effective beyond a placebo response? A systematic review with meta-analysis of randomised, sham controlled trials. *BMJ Open* **5**.
- Leucht S, Hierl S, Kissling W, Dold M, Davis JM (2012). Putting the efficacy of psychiatric and general medicine medication into perspective: review of meta-analyses. *The British Journal of Psychiatry* **200**, 97–106.

- Leucht S, Helfer B, Gartlehner G, Davis JM** (2015). How effective are common medications: a perspective based on meta-analyses of major drugs. *BMC Medicine* **13**, 253.
- Leucht S, Leucht C, Huhn M, Chaimani A, Mavridis D, Helfer B, Samara M, Rabaioli M, Bacher S, Cipriani A, Geddes JR, Salanti G, Davis JM** (2017). Sixty years of placebo-controlled antipsychotic drug trials in acute schizophrenia: systematic review, Bayesian meta-analysis, and meta-regression of efficacy predictors. *The American Journal of Psychiatry* **174**, 927–942.
- Mann K, Torup L, Sorensen P, Gual A, Swift R, Walker B, van den Brink W** (2016). Nalmefene for the management of alcohol dependence: review on its pharmacology, mechanism of action and meta-analysis on its clinical efficacy. *European Neuropsychopharmacology* **26**, 1941–1949.
- Messori A, Fadda V, Maratea D, Trippoli S** (2013). Acute lymphoblastic leukemia in first complete remission: temporal trend of outcomes in studies comparing allogeneic transplant with autologous transplant or chemotherapy. *Annals of Hematology* **92**, 1221–1228.
- Moncrieff J** (2008). The creation of the concept of an antidepressant: an historical analysis. *Social Science & Medicine* **66**, 2346–2355.
- Naci H, Smalley KR, Kesselheim AS** (2017). Characteristics of preapproval and postapproval studies for drugs granted accelerated approval by the US Food and Drug Administration. *JAMA* **318**, 626–636.
- Ostuzzi G, Papola D, Gastaldon C, Barbui C** (2017). New EMA report on paliperidone 3-month injections: taking clinical and policy decisions without an adequate evidence base. *Epidemiology and Psychiatric Sciences* **26**, 231–233.
- Sayer NA, Noorbaloochi S, Frazier PA, Pennebaker JW, Orazem RJ, Schnurr PP, Murdoch M, Carlson KF, Gravelly A, Litz BT** (2015). Randomized controlled trial of online expressive writing to address readjustment difficulties among U.S. Afghanistan and Iraq war veterans. *Journal of Traumatic Stress* **28**, 381–390.
- Seemuller F, Moller HJ, Dittmann S, Musil R** (2012). Is the efficacy of psychopharmacological drugs comparable to the efficacy of general medicine medication? *BMC Medicine* **10**, 17.
- Tatsioni A, Bonitsis NG, Ioannidis JP** (2007). Persistence of contradicted claims in the literature. *JAMA* **298**, 2517–2526.
- Taylor D, Sparshatt A, Varma S, Olofinjana O** (2014). Antidepressant efficacy of agomelatine: meta-analysis of published and unpublished studies. *BMJ* **348**, g1888.
- Turner EH, Matthews AM, Linardatos E, Tell RA, Rosenthal R** (2008). Selective publication of antidepressant trials and its influence on apparent efficacy. *The New England Journal of Medicine* **358**, 252–260.
- Turner EH, Knoopfelmacher D, Shapley L** (2012). Publication bias in antipsychotic trials: an analysis of efficacy comparing the published literature to the US Food and Drug Administration database. *PLoS Medicine* **9**, e1001189.
- Waszczuk MA, Li X, Bromet EJ, Gonzalez A, Zvolensky MJ, Ruggero C, Luft BJ, Kotov R** (2017). Pathway from PTSD to respiratory health: Longitudinal evidence from a psychosocial intervention. *Health Psychology* **36**, 429–437.